U.S. Online Retail and Ecommerce Stock News

Jones Lang LaSalle (JLL) at a glance Jones Lang LaSalle (JLL) has drawn fresh attention after recent trading left the shares at $320, with mixed return patterns over the past month and past 3 months prompting closer scrutiny from real estate focused investors. See our latest analysis for Jones Lang LaSalle. The recent 8.27% 1 month share price return contrasts with an 8.58% 3 month share price decline, while the 1 year total shareholder return of 50.02% points to momentum that has built up...

Earlier this week, Loews drew attention after its key subsidiary CNA Financial announced a 4% increase to its regular dividend and a special dividend on April 7, 2026, highlighting strong cash generation and management confidence at the insurance unit. The subsequent reassessment of this dividend news against a backdrop of choppy sentiment toward financial stocks has turned CNA’s payout decision into a broader gauge of how investors are weighing income potential against sector-wide...

In recent days, Dutch Bros has drawn fresh attention as multiple research firms initiated or upgraded coverage while the company continued rolling out new drive-thru locations across high-growth U.S. markets. This combination of favorable analyst commentary and evidence of disciplined expansion, underpinned by a highly penetrated loyalty program, has sharpened investor focus on the brand’s scalability and customer engagement. Now we’ll explore how this reinforced focus on disciplined unit...

In early April 2026, Oscar Health drew attention after CEO Mark Bertolini bought 1,000,000 shares for US$11.92 million and regulators finalized 2027 Medicare Advantage reimbursement increases that will add more than US$13.00 billion in payments across the industry. The combination of a rare insider purchase amid prior insider selling and policy-driven revenue tailwinds for managed-care players is prompting investors to reassess Oscar Health’s longer-term positioning and risk-reward...

Peoples Bancorp (PEBO) has drawn fresh attention after its share price moved above its long term average. This coincides with steadier banking sector conditions and renewed focus on the stock’s dividend and earnings outlook. See our latest analysis for Peoples Bancorp. The latest move above its long term average comes on top of a 9.19% 1 month share price return and a 12.49% 3 month share price return. The 1 year total shareholder return of 35.73% and 3 year total shareholder return of 60.23%...

Dubai launch puts Apollo Go in global focus Baidu (BIDU) is in the spotlight after Apollo Go launched a fully driverless commercial ride hailing service in Dubai, its first international app deployment and a key test of investor appetite for the stock. See our latest analysis for Baidu. Despite the Dubai launch drawing fresh attention to Apollo Go, Baidu’s share price has had a weaker patch, with a 1-month share price return of 13.76% and a year to date share price return of 27.99%. The...

Amylyx Pharmaceuticals recently saw increased analyst attention after the FDA approved its lead therapy AMX0035 for amyotrophic lateral sclerosis, reinforcing its focus on rare neurological diseases. This wave of analyst optimism underscores how regulatory progress on AMX0035 may influence expectations for Amylyx’s broader pipeline and long-term business potential. We’ll now explore how this renewed analyst confidence following AMX0035’s FDA approval could influence Amylyx Pharmaceuticals’...

ERP issues and legal investigation put DNOW (DNOW) under closer scrutiny DNOW (DNOW) is in focus after the Portnoy Law Firm began probing potential securities fraud, following the company’s disclosure that a new Enterprise Resource Planning system created operational issues and financial impacts. See our latest analysis for DNOW. At a share price of US$12.25, DNOW has seen a 5.33% 30 day share price return but a 9.73% 90 day share price decline. The 1 year total shareholder return of 18.82%...

The United States market has experienced a robust performance, climbing 3.4% in the last week and 30% over the past year, with earnings projected to grow by 16% annually. In such an environment, identifying stocks that may be undervalued can provide investors with opportunities to potentially capitalize on intrinsic value estimates that suggest significant upside potential.

The United States market has shown robust performance, climbing 3.4% in the last 7 days and rising 30% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, growth companies with high insider ownership often attract attention as they may signal strong confidence from those closest to the business's operations and future prospects.

The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. Although often considered a relic, penny stocks still hold potential when backed by solid fundamentals, offering a unique blend of value and growth that might not be found in larger companies.

The United States market has shown robust performance, rising 3.4% over the last week and climbing 30% in the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, identifying stocks that are not only underappreciated but also poised to capitalize on these favorable conditions can be particularly rewarding for investors seeking unique opportunities.

The market has climbed 3.4% in the last 7 days and is up 30% over the last 12 months, with earnings expected to grow by 16% per annum over the next few years. In such a robust environment, reliable dividend stocks can offer a steady income stream while potentially benefiting from overall market gains.

In the past week, Gulfport Energy reported solid quarterly results that built on several years of revenue expansion and consistently high gross margins. These margins, which have stayed elevated even when commodity prices were weaker, underline the company’s cost discipline and operational strength. Next, we’ll explore how Gulfport’s strong recent results and resilient margins might influence its existing investment narrative and risk profile. Uncover the next big thing with 32 elite penny...

In March 2026, Trex Company, Inc. amended and restated its prior credit facility, securing a revolving credit agreement of up to US$700,000,000 through March 26, 2031, backed by a broad package of collateral assets. This expanded, long-term credit access gives Trex greater financial flexibility for refinancing, working capital, capital spending, acquisitions, and other corporate uses without obligating the company to draw on the facility. We’ll now examine how Trex’s enlarged, long-duration...

KB Home recently announced it will relocate its corporate headquarters from Los Angeles to Tempe, Arizona by spring 2027, consolidating executive leadership and key functions in a more central, lower-cost and business-friendly Phoenix metro location. This move signals an effort to reshape the company’s cost base and operational footprint at a time when housing demand and margins are under pressure. We’ll now examine how the Tempe headquarters move, aimed at lowering structural costs, could...

Charles River Laboratories and Singapore-based NSG BioLabs recently signed a Memorandum of Understanding to combine NSG Bio’s infrastructure and community platform with Charles River’s global life sciences expertise, aiming to help biotech companies move more efficiently from early research to key development milestones. This collaboration not only expands Charles River’s presence in the Asia-Pacific region but also deepens its role as an end-to-end partner for emerging biotech...

Zai Lab Limited recently announced a global clinical trial collaboration with Amgen Inc. to test Zai Lab’s DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (zoci) in combination with Amgen’s IMDELLTRA in a Phase 1b study for patients with extensive-stage small cell lung cancer. This agreement, under which Amgen sponsors the study while Zai Lab retains full ownership of zoci and supplies the study drug, signals external confidence in Zai Lab’s oncology research platform and its...

In recent weeks, Surgery Partners has come under pressure from an activist investor campaign while appointing former CommonSpirit Health CEO Lloyd Dean as an independent director, against a backdrop of mixed analyst commentary on its operations and balance sheet. This combination of governance changes and concerns about weak unit sales and elevated net debt levels has sharpened focus on how the company may adjust its growth and financing approach. Next, we will explore how the activist...

In recent days, CarGurus reported a 15% year-over-year increase in fourth-quarter 2025 revenue, continued earnings and free cash flow margin improvements, and highlighted rising demand for fuel-efficient and used electric vehicles in its Q1 2026 market review. Together, this mix of stronger profitability and alignment with consumer shifts toward nearly new and fuel-efficient cars suggests CarGurus is increasingly positioned as a key platform in the evolving auto retail landscape. Next, we’ll...

The Defense Counterintelligence and Security Agency has recently awarded ICF International a position on a five-year, multiple-award blanket purchase agreement for software engineering services to modernize National Background Investigation Services systems, with a total ceiling of US$800 million shared across 12 vendors. This award not only confirms ICF’s Cybersecurity Maturity Model Certification Level 2 status but also positions the firm to pursue future task orders in cloud-native, zero...

Earlier this week, Damora Therapeutics highlighted recent corporate developments, including the appointment of Jennifer Jarrett as President and CEO and an FDA fast track designation for its ovarian cancer therapy candidate. Together, these changes spotlight how leadership decisions and regulatory milestones can reshape how investors think about a small biotech’s development pipeline and execution priorities. We’ll now examine how the FDA fast track designation, in particular, could...

In recent days, Public Service Enterprise Group increased its 2026–2030 capital program from US$24.00 billion to US$28.00 billion and raised its long-term adjusted earnings growth outlook, while its New Jersey energy efficiency initiatives continued delivering hundreds of millions of dollars in annual customer savings and emissions reductions. These moves highlight how rising power demand and policy support are encouraging PSEG to double down on grid investments and efficiency programs that...

Boyd Gaming (BYD) is back in focus after topping analyst revenue expectations in its latest quarter, even as adjusted operating income lagged, and as a new court ruling opens additional online betting possibilities in New Jersey. See our latest analysis for Boyd Gaming. The share price reaction around earnings and the New Jersey ruling has been positive, with an 8.23% 1 month share price return and a 36.28% 1 year total shareholder return suggesting momentum is improving after a softer 90 day...